LABORATORY-SCALE CULTIVATION OF THE OSPA-VAKTSINA VACCINIA VIRUS STRAIN IN VERO CELLS ON BIONOC II® MACROCARRIERS USING THE BELLOSTAGE™-3000 SYSTEM
Main Article Content
Authors
Zh.T. Amanova
Research Institute for Biological Safety Problems LLP, National Holding “QazBioPharm”, Gvardeyskiy, Korday District, Zhambyl Region, 25/1, 080409, Kazakhstan
Zh.Zh. Sametova
Research Institute for Biological Safety Problems LLP, National Holding “QazBioPharm”, Gvardeyskiy, Korday District, Zhambyl Region, 25/1, 080409, Kazakhstan
Ye.A. Bulatov
Research Institute for Biological Safety Problems LLP, National Holding “QazBioPharm”, Gvardeyskiy, Korday District, Zhambyl Region, 25/1, 080409, Kazakhstan
Abstract
Vaccinia virus remains relevant as a viral substrate for smallpox vaccines and as an orthopoxvirus model. This study evaluated, at laboratory scale, the feasibility of cultivating the “Ospa-vaktsina” vaccinia virus strain in Vero cells grown on BioNOC II® macrocarriers using the BelloStage™-3000 Tide Motion system. The study was not designed as a comparative assessment of BelloStage™-3000 performance against another cultivation platform.
Vero cells were cultivated in BelloCell®-500A vessels in Dulbecco’s Modified Eagle Medium supplemented with 2% fetal bovine serum. After 120 h of cell cultivation, when the total cell number reached 1.99 × 10⁹ cells per vessel, cultures were infected with a working virus inoculum at a calculated infectious input of 0.01 TCID₅₀ per cell. The infectious input was calculated as the total TCID₅₀ delivered in the 500-mL inoculum divided by the total cell number at infection. One bioreactor run included three parallel BelloCell®-500A vessels (n = 3 culture units within a single run).
Cell attachment to the macrocarriers was 89% at 3 h after seeding. The total cell number increased from 7.45 × 10⁷ cells at seeding to 1.99 × 10⁹ cells per vessel at 120 h, corresponding to a 26.7-fold increase. Following infection, the virus titer increased from 4.60 log₁₀ TCID₅₀/mL in the working inoculum to a maximum of 6.00 log₁₀ TCID₅₀/mL at 120 h post-infection, a 1.40-log₁₀ (approximately 25.1-fold) increase. Culture medium parameters were maintained within predefined operating ranges for the cell-growth and post-infection phases.
Under the conditions tested, the Vero/BioNOC II® culture supported replication of the “Ospa-vaktsina” strain in BelloStage™-3000. Because the study comprised a single bioreactor run and did not include a parallel comparator platform, the findings demonstrate laboratory-scale feasibility but do not establish technological superiority, process scalability, or suitability for vaccine manufacturing.
Keywords
Vaccinia virus, Vero cells, cultivation, bioreactor, BioNOC II® macrocarriers, Tide Motion
Article Details
References
Ahmed, S. F., Sohail, M. S., Quadeer, A. A., & McKay, M. R. (2022). Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. Viruses, 14(9), 1960. Crossref
Berry, M. T., Khan, S. R., Schlub, T. E., Notaras, A., Kunasekaran, M., Grulich, A. E., MacIntyre, C. R., Davenport, M. P., & Khoury, D. S. (2024). Predicting vaccine effectiveness for mpox. Nature communications, 15(1), 3856. Crossref
Shafaati, M., Forghani, S., Shahsavand Davoudi, A., Samiee, R., Mohammadi, K., Akbarpour, S., Seifi, A., Salehi, M., & Zare, M. (2025). Current advances and challenges in mpox vaccine development: a global landscape. Therapeutic advances in vaccines and immunotherapy, 13, 25151355251314339. Crossref
Williamson A. L. (2025). Approaches to Next-Generation Capripoxvirus and Monkeypox Virus Vaccines. Viruses, 17(2), 186. Crossref
Esco Aster Pte. Ltd. BelloStage™-3000 and BelloCell™ Technical Brochure. Singapore: Esco Aster; 2024.
VacciXcell Co., Ltd. BelloCell™ and CelCradle™ Technical Documentation. Taiwan: VacciXcell Co., Ltd.; 2025.
Lu, JT., Chung, YC., Chan, ZR. et al. A Novel Oscillating Bioreactor BelloCell: Implications for Insect Cell Culture and Recombinant Protein Production. Biotechnol Lett 27, 1059–1065 (2005). Crossref
Offersgaard, A., Duarte Hernandez, C. R., Pihl, A. F., Costa, R., Venkatesan, N. P., Lin, X., Van Pham, L., Feng, S., Fahnøe, U., Scheel, T. K. H., Ramirez, S., Reichl, U., Bukh, J., Genzel, Y., & Gottwein, J. M. (2021). SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. Vaccines, 9(7), 706. Crossref
Offersgaard, A., Duarte Hernandez, C. R., Pihl, A. F., Venkatesan, N. P., Krarup, H., Lin, X., Reichl, U., Bukh, J., Genzel, Y., & Gottwein, J. M. (2022). High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. Vaccines, 10(2), 249. Crossref
Rhazi, H., Safini, N., Mikou, K., Alhyane, M., Tadlaoui, K. O., Lin, X., Venkatesan, N. P., & Elharrak, M. (2021). Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors. BMC veterinary research, 17(1), 93. Crossref
Choi, H. Y., Choi, J. C., Kang, Y. L., Ahn, S. H., Lee, S. W., Park, S. Y., Song, C. S., Choi, I. S., & Lee, J. B. (2023). Production of a chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine using a lab-scale packed-bed bioreactor CelCradle. BMC veterinary research, 19(1), 105. Crossref
Guo H, Ding X, Hua D, Liu M, Yang M, Gong Y, Ye N, Chen X, He J, Zhang Y, et al. Enhancing Dengue Virus Production and Immunogenicity with Celcradle™ Bioreactor: A Comparative Study with Traditional Cell Culture Methods. Vaccines. 2024; 12(6):563. Crossref
Kiesslich, S., & Kamen, A. A. (2020). Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnology advances, 44, 107608. Crossref
Amanova, Z., Sametova, Z., Chervyakova, O., Turyskeldi, S., Kurmasheva, A., Abitayev, R., Ussembay, A., Kondibayeva, Z., Toktyrova, D., Mazbayeva, D., & Bulatov, Y. (2025). BelloStage™-3000 Bioreactor Versus Conventional Cultivation of Recombinant Capripoxvirus Expressing Brucella Antigens in Vero Cells: A Step Towards the Development of a New Human Brucellosis Vaccine. Cells, 14(20), 1631. Crossref
Amanova, Z., Sametova, Z., Turyskeldy, S., Kurmasheva, A., Abitayev, R., Ussembay, A., Kondibaeva, Z., Toktyrova, D., Mazbayeva, D., Nurabayev, S., Kerimbayev, A., & Bulatov, Y. (2025). Efficient Serum-Free Rabies Virus Propagation Using BSR and Vero Cell Lines: A Comparative Evaluation of BioNOC II® Macrocarriers in the BelloStage™-3000 Bioreactor Versus Conventional Microcarriers. Biology, 14(10), 1455. Crossref
Mazhed, Z. K., Vasilenko, V. E., Siniugina, A. A., Kaa, K. V., Motov, A. S., Pokidova, K. O., Ivin, Y. Y., Piniaeva, A. N., Khapchaev, Y. K., Chernov, K. A., & Ishmukhametov, A. A. (2025). Intensification of Vero cell adherence to microcarrier particles during cultivation in a wave bioreactor. Frontiers in bioengineering and biotechnology, 13, 1542060. Crossref
Fang, Z., Lyu, J., Li, J., Li, C., Zhang, Y., Guo, Y., Wang, Y., Zhang, Y., & Chen, K. (2022). Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects. Frontiers in bioengineering and biotechnology, 10, 921755. Crossref
Ton, C., Stabile, V., Carey, E., Maraikar, A., Whitmer, T., Marrone, S., Afanador, N. L., Zabrodin, I., Manomohan, G., Whiteman, M., & Hofmann, C. (2023). Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor. Biotechnology reports (Amsterdam, Netherlands), 37, e00782. Crossref
Tapia, F., Jordan, I., Genzel, Y., & Reichl, U. (2017). Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems. PloS one, 12(8), e0182553. Crossref
Gränicher, G., Tapia, F., Behrendt, I., Jordan, I., Genzel, Y., & Reichl, U. (2021). Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production. Biotechnology journal, 16(1), e2000024. Crossref